This trial is for those with a diagnosis of clear cell carcinoma that has recurred (come back). It is an open label study, which means both you and the doctor know what treatment you are receiving. Clear cell carcinoma (CCC) is a rare subtype of ovarian cancer. Treatment for recurrent CCC is usually chemotherapy. The researchers conducting the tria…

The trial is currently recruiting patients who have experienced a recurrence of ovarian, fallopian, or primary peritoneal cancer six months or more after receiving platinum-based chemotherapy. Maintenance treatments (also known as targeted treatments)work on specific genes and proteins that are involved in the growth and survival of cancer cells. T…

In cases where ovarian, fallopian tube or peritoneal cancer has come back (recurrence or relapse) and it has become resistant to platinum-based chemotherapy, new treatment strategies and new drugs are needed to better treat this disease. This study tests a new drug both in combination with a known treatment and alone, to find out if the differe…

The study aims to find out the answers to the following questions: Is one of these treatment approaches better than the other? Which treatment causes fewer side effects? Which treatment offers a better quality of life? Is it safe to use bevacizumab to treat women who are having surgery at the same time as chemotherapy? If you take …